Treatment options for patients with diabetes and chronic kidney disease (CKD) have improved significantly thanks to new therapeutic options from the SGLT-2-i, GLP-1-RA and MRA drug classes. The new guidelines issued last year by KDIGO (Kidney Disease: Improving Global Outcomes) aim to provide practical guidance for use in everyday clinical practice. How barriers to implementing these recommendations can be overcome was discussed at this year’s European Renal Association (ERA) Congress.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- HAUSARZT PRAXIS
